Sunshine Biopharma Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Sunshine Biopharma Inc. (SBFM) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $912.96 thousand for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2016-11-14
- Sunshine Biopharma Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2016-09-30 was $646.40K.
- Sunshine Biopharma Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2016-06-30 was $148.62K.
- Sunshine Biopharma Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2016-03-31 was $117.94K.
- Sunshine Biopharma Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2015-12-31 was $454.89K.
- Sunshine Biopharma Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2013 was $498.30K, a 251.93% increase from fiscal 2012.
- Sunshine Biopharma Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2012 was $141.59K.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|---|
| 2016-09-30 | $646.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $795.02K derived: sum of 2 quarters · filed 2016-11-14 | $912.96K 10-Q · filed 2016-11-14 | $1.37M derived: sum of 4 quarters · filed 2016-11-14 |
| 2016-06-30 | $148.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-16 | $266.55K 10-Q · filed 2016-08-16 | $721.44K derived: sum of 3 quarters · filed 2016-11-14 | |
| 2016-03-31 | $117.94K 10-Q · filed 2016-05-09 | $572.82K derived: sum of 2 quarters · filed 2016-11-14 | ||
| 2015-12-31 | $454.89K derived: 10-Q 12 month − 10-Q 9 month · filed 2016-11-14 | $843.21K 10-Q · filed 2016-11-14 | ||
| 2015-09-30 | $388.32K 10-Q · filed 2015-11-04 | |||
| 2014-12-31 | $747.18K 10-Q · filed 2015-11-04 | |||
| 2013-12-31 | $498.30K 10-K · filed 2014-03-19 | |||
| 2012-12-31 | $141.59K 10-K · filed 2014-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |